GLMD Galmed Pharmaceuticals
- 0.3790
- -0.0126-3.22%
- 0.3844
- +0.0054+1.42%
Galmed Pharmaceuticals News
Galmed Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Galmed Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Galmed Pharmaceuticals | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Galmed Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Galmed Pharmaceuticals | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Galmed Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Galmed Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Galmed Pharmaceuticals | 6-K/A: Report of foreign private issuer [Rules 13a-16 and 15d-16] (Amendment)
Galmed Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Galmed Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Galmed Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Galmed Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Galmed Pharmaceuticals | F-1/A: Registration statement for securities of certain Canadian issuers (Amendment)
Galmed Pharmaceuticals | F-1/A: Registration statement for securities of certain Canadian issuers (Amendment)
Galmed Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Galmed Pharmaceuticals | F-1/A: Registration statement for securities of certain Canadian issuers (Amendment)
Galmed Pharmaceuticals | F-1: Registration statement for securities of certain foreign private issuers
Galmed Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Galmed Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Galmed Pharmaceuticals | 6-K: Report of foreign issuer [Rules 13a-16 and 15d-16]
Analysis
Price Target
No Data
